ReviewExperimental & molecular medicine2026
Pyroptosis: mechanism and therapeutic strategies with intervertebral disc degeneration.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Challenge-Oriented Review of Delivery Systems for Cell and Gene Therapies in Intervertebral Disc Degeneration.Bioengineering (Basel, Switzerland) · 2026Review
- Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IDD) is a major cause of low back pain, characterized by a complex interplay of inflammation, extracellular matrix degradation and various modes of cell death. Among these, pyroptosis, a highly inflammatory form of programmed cell death, has recently emerged as a critical pathogenetic mechanism. This review systematically elaborates on the role of pyroptosis in IDD, detailing its activation via the canonical and noncanonical inflammasome pathways in response to oxidative stress, mechanical load and metabolic disturbances. Here we highlight how pyroptosis synergizes with other pathological processes, creating a vicious cycle that accelerates disc degeneration. Furthermore, we critically evaluate promising therapeutic strategies that target pyroptosis, including small molecule inhibitors, biological agents, stem cell-derived extracellular vesicles and innovative biomaterial-based delivery systems designed to overcome the challenges of the avascular disc microenvironment. Finally, we discuss the translational potential and future directions of antipyroptosis therapies, proposing an integrated approach for managing IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.